Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 20, 2019
Reporting Period: Event date May 20, 2019; Report signed May 24, 2019.
Context: The Company entered into a material definitive agreement involving a sublease for office space.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the terms of a new lease agreement.
Sublease Financial Terms
| Lease Period | Monthly Base Rent |
|---|---|
| Months 1-12 | $4,108.75 |
| Months 13-24 | $4,232.00 |
| Months 25-36 | $4,358.95 |
| Months 37-48 | $4,489.72 |
| Months 49-60 | $4,624.41 |
| Month 61 | $4,763.14 |
Total Term: 61 months, commencing upon substantial completion of tenant improvements (estimated June 1, 2019).
Material Changes and Related Party Transaction
The Company entered into a sublease with CTI-Clinical Trial Services, Inc. This is a related party transaction as Timothy J. Schroder, the Chief Executive Officer and owner of CTI-Clinical Trial Services, Inc., is also a member of Inmune Bio's Board of Directors.
Guidance, Outlook, and Risks
Management Commentary: The filing provides no forward-looking guidance, outlook, or general management commentary beyond the execution of the lease.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies, though the related party nature of the transaction is disclosed. The full text of the Sublease is attached as Exhibit 10.1 and incorporated by reference.
Investor Verification Checklist
- Verify the related party relationship between Inmune Bio and CTI-Clinical Trial Services, Inc. via the Board of Directors composition.
- Review the full text of the Sublease (Exhibit 10.1) for additional covenants, termination rights, or expense responsibilities not detailed in the summary.
- Confirm the estimated start date of June 1, 2019, and the status of tenant improvements.
- Assess the impact of the escalating rent schedule on future operating expenses.